Aşırı Aktif Mesane hastalarında semptomları gidermede hangisi daha etkili: Trospium 30 mg 2x1 ya da solifenasin 5 mg 1x1
Amaç: Aşırı Aktif Mesane (AAM) hastalarında trospium ve solifenasinin işeme sayısı, nokturi ve urge inkontinans üzerine etkilerini araştırmak. Gereç ve Yöntem: Prospektif bir çalışma planlandı. Hastalar tedaviye başlamadan önce AAM farkındalık anketini (AAM-V8) doldurdular. Hastaların 3 günlük işeme günlüğünden günlük işeme, nokturi ve urge inkontinans sayıları belirlendikten sonra trospium 30 mg 2x1 veya solifenasin 5 mg 1x1 den birisi başlandı. Hastalar kontrolde işeme günlüğü ve AAM-V8 formu ile tekrar değerlendirildi. Ayrıca yan etkiler sorgulandı. Bulgular: Bu çalışma yaş ortalaması 47.8±12.2(18-75 yaş) olan toplam 225 hasta içermektedir. Hastaların 173(76.9%)’sı kadın, 52(23.1%)’si erkektir. Trospium grubunda(n=104, M/F:24/80) yaş ortalaması 47.4±12.7 ve solifenasin grubunda(n=121, M/F:28/93) yaş ortalaması 48.1±11.8 olup gruplar arasında istatistiksel farklılık izlenmedi (p=0.657). Validasyon ölçeği anketinde azalmada iki molekül arasında istatistiksel farklılık izlenmedi. Hem 4.hafta hemde 12.haftada işeme sayısı trospium molekülünde solifenasin den daha fazla azalmıştır ve bu azalmalar istatistiksel olarak anlamlıdır (sırasıyla p<0.027, p<0.045 ). Nokturi ve urge inkontinans sayıları azaldı fakat trospium ve solifenasin molekülleri arasında farklılık izlenmedi. En sık izlenen yan etkiler ağız kuruluğu, kabızlık ve bulanık görmedir. Sonuç: Her iki molekülde AAM hastalarında 4.hafta ve 12.haftalarda validasyon ölçeğini, işeme sayısı, nokturi ve urge inkontinans sayılarını azaltır. İşeme sayısını trospium molekülü solifenasin den daha fazla azaltmıştır ve bu azalma istatistiksel olarak anlamlıdır. Özellikle işeme sayısı fazlalığından yakınan AAM hastalarında trospium molekülü solifenasinden daha etkili olabilir.
Which one is more effective for symptom relief in overactive bladder patients: Trospium 30 mg 2x1 or solifenacin 5 mg 1x1
Aim: To investigate the effect of trospium and solifenacin on the micturition, nocturia and urge incontinence numbers in overactive bladder (OAB). Material and Method: A prospective study was planned. The patients completed the OAB awareness survey (OAB-V8) before starting the treatment. The patient’s daily micturition, nocturia and urge incontinence numbers were recorded from the 3-day voiding diaries and one of trospium 30 mg bd or solifenacin 5 mg od was started. The patients were evaluated again at follow-up using the voiding diary and the OAB-V8 form. Results: The study included a total of 225 subjects aged 18-75 years with a mean age of 47.8±12.2 years. There were 173 (76.9%) females and 52 (23.1%) males. The mean age was 47.4±12.7 in the trospium (n=104, M/F:24/80) and 48.1±11.8 years in the solifenacin (n=121, M/F:28/93) with no statistically significant difference (p=0.657). No statistically significant difference was found between the two molecules regarding the decrease in the validation scale. The micturition number at both the 4th and 12th weeks decreased more markedly with trospium then solifenacin and the difference was statistically significant (p<0.027 and p<0.045 respectively). The nocturia and urge incontinence numbers decreased as well but without a statistically significant difference between the trospium and solifenacin. The most common side effects were dry mouth, constipation and blurred vision. Conclusions: Both molecules decreased the micturition, nocturia and urge incontinence numbers in addition to the validation scale values at the 4th and 12th weeks in OAB patients. There was no difference between the two molecules as regards decreasing the nocturia and urge incontinence numbers and validation scale values. The trospium decreased micturition numbers more than the solifenacin and this difference was statistically significant. Trospium could be more effective than solifenacin in the treatment of OAB patients, especially those complaining of increased micturition numbers.
___
- Jain D, Dhua A, Ravisankar V, Chellam L, Joshi M.J. Acute
angle closure gloucoma after hypospadias surgery: A vision-
threatening complication of oxybutyning. J Indian Assoc
Pediatr Surg 2015;20: 161-2.
- 2. Zumrutbas AE, Bozkurt AI, Tas E, Acar CI, Alkis O, Coban
K, Cetinel B, Aybek Z. Prevalence of lower urinary tract
symptoms, overactive bladder and urinary incontinence in
western Turkey: results of a population-based survey. Int J
Urol 2014;21:1027-33.
- 3. Homma Y, Kakizaki H, Gotoh M. Epidemiologic survey on
urination. J Jpn Neurogenic Bladder Soc 2003;14:266-77.
- 4. Andersson K-E, Yoshida M. Antimuscarinics and the overactive
detrusorwhich is the main mechanism of action? Eur
Urol 2003;43:1-5.
- 5. Doroshyenko O, Jetter A, Odenthal KP, Fuhr U. Clinical
pharmacokinetics of trospium. Clin Pharmacokinet
2005;44:701-20.
- 6. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ,
Burcher E. Muscarinic receptor subtypes in human bladder
detrusor and mucosa, studied by radioligand binding and
quantitative competitive RT-PCR: changes in ageing. Br J
Pharmacol 2005;144:1089-91.
- 7. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine
receptor subtypes mediating urinary bladder contractility
and coupling to GTP binding proteins. J Pharmacol Exp
Ther 1995;273:959-66.
- 8. Lai HH, Boone T, Appell RA. Selecting a medical therapy
for overactive bladder. Rev Urol 2002;4:28-37.
- 9. Coyne K, Revicki D, Hunt T et al. Psychometric validation
of an overactive bladder symptom and health-related
quality of life questionnaire: the OAB-q. Qual Life Res
2002;11:563-74.
- 10. Acquadro C, Kopp Z, Coyne KS et al. Translating overactive
bladder questionnaires in 14 languages. Urology
2006;67:536-40.
- 11. Tarcan T, Mangır N, Özgür MO, Gümrah A, Akbal C. Constitution
and Validation of a New Symptom Assessment
Tool for Overactive Bladder: Marmara Overactive Bladder
Questionnaire (M-OBQ). Journal of Urological Surgery
2014; 1: 24-27.
- 12. Garnett S, Swithinbank L, Ellis-Jones J, Abrams P. The
long-term natural history of overactive bladder symptoms
due to idiopathic detrusor overactivity in women. BJU Int
2009;104:948-53.
- 13. Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner
TH. Impact of overactive bladder on work productivity in
Yeni Üroloji Dergisi - The New Journal of Urology 2018; 13 (1): 39-45
45
- the United States: results from EpiLUTS. Am J ManagCare
2009;15:98-107.
- 14. Hartmann KE, McPheeters ML, Biller DH, Ward RM,
McKoy JN, Jerome RN. Treatment of overactive bladder in
women. Evid Rep Technol Assess 2009; 187:1.
- 15. Andersson KE, Wein AJ. Pharmacologic Management of
Lower Urinary Tract Storage and Emptying Failure. Campbell’s
Urology (Kavoussi LR, Partin AW, Novick AC, Peters
CA, ed). Tenth edition. Saunders Elsevier. Vol 3, Section
XIV 2012; p 1967-2002.
- 16. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE,
Weinstein D. The effects of antimuscarinic treatments in
overactive bladder: an update of a systematic review and
meta-analysis. Eur Urol 2008;54: 543-62.
- 17. Junemann KP, Al-Shukrı S. Efficacy and tolerability of trospium
and tolterodine in 234 patients with urge syndrome: a
double-blind, placebo-controlled, multicentre clinical trial.
Neurourol. Urodyn 2000;19:488-90.
- 18. Halaska M, Ralph G, Wiedemann A et al. Controlled, double-
blind, multicentre clinical trial to investigate long-term
tolerability and efficacy of trospium in patients with detrusor
instability. World J. Urol 2003;20:392-9.
- 19. Dugan E, Cohen SJ, Bland DR et al. The association of depressive
symptoms and urinary incontinence among older
adults. J. Am. Geriatr. Soc 2000; 48:413-6.
- 20. Irwin DE, Abrams P, Milsom I, Kopp Z, Reilly K; EPIC Study
Group. Understanding the element of overactive bladder:
questions raised by the EPIC study. BJU Int 2008;101:1381-7.
- 21. Herschorn S, Gajewski J, Schulz J, Corcos J. A populationbased
study of urinary symptoms and incontinence: the Canadian
urinary bladder survey BJU Int 2008;101:52-8.
- 22. Basra R, Kelleher C. Disease burden of overactive bladder:
quality-of-life data assessed using ICI-recommended instruments.
Pharmacoeconomics 2007;25:129-42.
- 23. Zınner N, Geıttelman M, Harrıs R, Susset J, Kanellos
A, Auerbach S. Trospium chloride improves overactive
bladder symptoms: a multicenter Phase III trial. J.Urol
2004;171:2311-5.
- 24. Yoshida A, Fujino T, Maruyama S, Ito Y, Yamada S. The forefront
for novel therapeutic agents based on the pathophysiology
of lower urinary tract dysfunction: bladder sensitivity
based on in vivo drug-receptor binding characteristics of
antimuscarinic agents for treatment of over active bladder. J
Pharmacol Sci 2010; 112: 142-50.
- 25. Lam S, Hilas O. Pharmacologic management of overactive
bladder. Clin Int Aging 2007; 2:337-45.
- 26. Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M.
Symptom bother and health-related quality of life outcomes
following solifenacin treatment for overactive bladder:
the VESIcare Open-Label Trial (VOLT). Clin Ther
2006;28:1935–46.